Dive into a wealth of investment research & market commentary

Access free, quality analysis on a wide range of markets. Subscribe to get premium insights from analysts you trust.

The First Open-Access Platform for Investment Research

Open Access

ResearchPool’s open and user-friendly research marketplace lets you download and analyse information faster. Improved search allows you to focus on the insights that are relevant to you.

Flexible Payment Options

In preparation for an unbundled research market under MiFID II, ResearchPool provides flexible payment options for premium reports. Pay for reports per view or with our new subscription service. Whichever method you choose, price transparency allows you to formulate a more controlled budget plan.

One-stop-shop

Download free and premium reports covering key financial asset classes. These include equity, credit, commodities, real estate, money markets, currencies, multi-asset and alternatives. Whatever insights you need to make the right decision, you can find them here.

A Platform For Both Investors & Providers

ResearchPool is designed to help professional and individual investors find relevant research on their own terms. However, it is also a streamlined platform for research providers and analysts to monetize and get their insights out to a wider audience. Upload your research through our provider gateway and watch as your profile page grows and reports are shared.

Latest reports

IMV Inc - Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting

by BusinessWire
08/12/2019 1 pages English FREE Read Now

KURA ONCOLOGY - Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

by GlobeNewsWire
08/12/2019 1 pages English FREE Read Now

Fate Therapeutics Inc - Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy

by GlobeNewsWire
08/12/2019 1 pages English FREE Read Now

Seluxit - Seluxit signs an agreement with a new client within the healthcare industry

by GlobeNewsWire
08/12/2019 1 pages English FREE Read Now

Seluxit - Seluxit indgår en aftale med en kunde indenfor sundhedssektoren.

by GlobeNewsWire
08/12/2019 1 pages English FREE Read Now

Autolus Therapeutics ADS - Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies

by GlobeNewsWire
08/12/2019 1 pages English FREE Read Now

Innate Pharma SA - Innate Pharma présente Lumoxiti®, médicament approuvé par la FDA, au congrès de l'ASH 2019

by GlobeNewsWire
08/12/2019 1 pages English FREE Read Now

Innate Pharma SA - Innate Pharma Highlights FDA-Approved Lumoxiti® at ASH 2019

by GlobeNewsWire
08/12/2019 1 pages English FREE Read Now

ZIOPHARM Oncology - Ziopharm Oncology Presents Pre-Clinical Data Validating “Rapid Personalized Manufacture” (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting

by GlobeNewsWire
08/12/2019 1 pages English FREE Read Now

TG Therapeutics Inc - TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition

by GlobeNewsWire
08/12/2019 1 pages English FREE Read Now

ResearchPool features

Up-to-date and historic research

Get easy access to financial research and white papers so you never fall behind. Stay up-to-date on the latest regulatory developments within the European capital markets.

Always high quality content

All research is contributed by regulated research providers who check for quality and accuracy. Peace of mind guaranteed.

Sign up to get access to thousands of free and premium reports

ResearchPool Subscriptions

Get the most out of your insights

Get in touch